| Year |
Citation |
Score |
| 2019 |
Pang Y, Khatri A, Suleiman AA, Othman AA. Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients. Clinical Pharmacokinetics. PMID 31758502 DOI: 10.1007/S40262-019-00842-5 |
0.387 |
|
| 2019 |
Suleiman AA, Khatri A, Oberoi RK, Othman AA. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis. Clinical Pharmacokinetics. PMID 31667790 DOI: 10.1007/S40262-019-00829-2 |
0.355 |
|
| 2019 |
Witjes H, Khatri A, Diderichsen PM, Mandema J, Othman AA. Meta-analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority. Clinical Pharmacology and Therapeutics. PMID 31502263 DOI: 10.1002/Cpt.1624 |
0.325 |
|
| 2019 |
Khatri A, Suleiman AA, Polepally AR, Othman AA. Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase 2 and 3 Trials in Psoriasis Patients. Clinical Pharmacology and Therapeutics. PMID 31355921 DOI: 10.1002/Cpt.1594 |
0.36 |
|
| 2019 |
Khatri A, Eckert D, Oberoi R, Suleiman A, Pang Y, Cheng L, Othman AA. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis. Journal of Clinical Pharmacology. PMID 31257614 DOI: 10.1002/Jcph.1473 |
0.372 |
|
| 2019 |
Suleiman AA, Minocha M, Khatri A, Pang Y, Othman AA. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials. Clinical Pharmacokinetics. PMID 31054118 DOI: 10.1007/S40262-019-00759-Z |
0.317 |
|
| 2018 |
Khatri A, Cheng L, Camez A, Ignatenko S, Pang Y, Othman AA. Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis. Clinical Pharmacokinetics. PMID 30574672 DOI: 10.1007/S40262-018-0730-X |
0.308 |
|
| 2018 |
Khatri A, Klünder B, Peloso PM, Othman AA. Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis. Rheumatology (Oxford, England). PMID 30376130 DOI: 10.1093/Rheumatology/Key312 |
0.301 |
|
| 2018 |
Shuster DL, Menon RM, Ding B, Khatri A, Li H, Cohen E, Jewett M, Cohen DE, Zha J. Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials. European Journal of Clinical Pharmacology. PMID 30291369 DOI: 10.1007/S00228-018-2566-6 |
0.352 |
|
| 2018 |
Othman AA, Khatri A, Loebbert R, Peloso PM. Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis. Clinical Pharmacology in Drug Development. PMID 30156758 DOI: 10.1002/Cpdd.611 |
0.36 |
|
| 2018 |
Khatri A, Othman AA. Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials. Journal of Clinical Pharmacology. PMID 29364523 DOI: 10.1002/Jcph.1068 |
0.361 |
|
| 2017 |
Khatri A, Goss S, Jiang P, Mansikka H, Othman AA. Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. Clinical Pharmacokinetics. PMID 28744796 DOI: 10.1007/S40262-017-0580-Y |
0.308 |
|
| 2017 |
Polepally AR, Wang H, Marroum PJ, Minocha M, Hosmane B, Khatri A, Mensing S, Podsadecki TJ, Cohen DE, Awni WM, Menon RM. Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection. The Aaps Journal. PMID 28685397 DOI: 10.1208/S12248-017-0115-3 |
0.457 |
|
| 2017 |
Wyles D, Saag M, Viani RM, Lalezari J, Adeyemi O, Bhatti L, Khatri A, King JR, Hu YB, Trinh R, Shulman NS, Ruane P. TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir. The Journal of Infectious Diseases. PMID 28329334 DOI: 10.1093/Infdis/Jiw597 |
0.396 |
|
| 2017 |
King JR, Zha J, Khatri A, Dutta S, Menon RM. Clinical Pharmacokinetics of Dasabuvir. Clinical Pharmacokinetics. PMID 28258380 DOI: 10.1007/S40262-017-0519-3 |
0.444 |
|
| 2017 |
Menon RM, Polepally AR, Khatri A, Awni WM, Dutta S. Clinical Pharmacokinetics of Paritaprevir. Clinical Pharmacokinetics. PMID 28236252 DOI: 10.1007/S40262-017-0520-X |
0.467 |
|
| 2016 |
King JR, Khatri A, Trinh R, Viani RM, Ding B, Zha J, Menon R. Pharmacokinetic Evaluation of Darunavir Administered Once or Twice daily in Combination with Ritonavir or the Three Direct Acting Antiviral Regimen of Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir in Adults Co-infected with Hepatitis C and Human Immunodeficiency Virus. Antimicrobial Agents and Chemotherapy. PMID 27919899 DOI: 10.1128/Aac.02135-16 |
0.405 |
|
| 2016 |
Mensing S, Eckert D, Sharma S, Polepally AR, Khatri A, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir, and ribavirin in hepatitis C virus genotype 1 infection: analysis of 6 phase 3 trials. British Journal of Clinical Pharmacology. PMID 27662429 DOI: 10.1111/Bcp.13138 |
0.423 |
|
| 2016 |
Khatri A, Trinh R, Zhao W, Podsadecki T, Menon R. Drug-Drug Interaction Between the Direct-acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir and the HIV Antiretroviral Agents Dolutegravir or Abacavir Plus Lamivudine. Antimicrobial Agents and Chemotherapy. PMID 27503645 DOI: 10.1128/Aac.00795-16 |
0.41 |
|
| 2016 |
Khatri A, Dutta S, Marbury TC, Preston RA, Rodrigues L, Wang H, Awni WM, Menon RM. Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment. Clinical Pharmacokinetics. PMID 27389403 DOI: 10.1007/S40262-016-0429-9 |
0.44 |
|
| 2016 |
Gopalakrishnan SM, Polepally AR, Mensing S, Khatri A, Menon RM. Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection. Clinical Pharmacokinetics. PMID 27314261 DOI: 10.1007/S40262-016-0423-2 |
0.44 |
|
| 2016 |
Shen J, Serby M, Reed A, Lee AJ, Zhang X, Marsh K, Khatri A, Menon R, Kavetskaia O, Fischer V. Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 27179127 DOI: 10.1124/Dmd.115.067488 |
0.403 |
|
| 2016 |
Khatri A, Mensing S, Podsadecki T, Awni W, Menon R, Dutta S. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients. Clinical Drug Investigation. PMID 27153823 DOI: 10.1007/S40261-016-0407-X |
0.424 |
|
| 2016 |
Gopalakrishnan S, Khatri A, Mensing S, Redman R, Menon R, Zha J. Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study. Advances in Therapy. PMID 27084721 DOI: 10.1007/S12325-016-0320-Y |
0.399 |
|
| 2016 |
Polepally AR, Mensing S, Khatri A, Beck D, Liu W, Awni WM, Menon RM, Dutta S. Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Clinical Pharmacokinetics. PMID 27000758 DOI: 10.1007/S40262-016-0385-4 |
0.455 |
|
| 2016 |
Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, Bernstein DE, Cohen DE, Shulman NS, Wang D, Khatri A, Abunimeh M, Podsadecki T, Lawitz E. Efficacy of Direct-acting Antiviral Combination for Patients with HCV Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology. PMID 26976799 DOI: 10.1053/J.Gastro.2016.02.078 |
0.393 |
|
| 2016 |
Khatri A, Dutta S, Dunbar M, Podsadecki T, Trinh R, Awni W, Menon R. Evaluation of Drug-Drug Interactions Between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine. Antimicrobial Agents and Chemotherapy. PMID 26953200 DOI: 10.1128/Aac.02605-15 |
0.404 |
|
| 2016 |
Polepally AR, King JR, Ding B, Shuster DL, Dumas EO, Khatri A, Chiu YL, Podsadecki TJ, Menon RM. Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers. Clinical Pharmacokinetics. PMID 26895022 DOI: 10.1007/S40262-016-0373-8 |
0.381 |
|
| 2016 |
Khatri A, Dutta S, Wang H, Podsadecki T, Trinh R, Awni W, Menon R. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 26740513 DOI: 10.1093/Cid/Civ1213 |
0.377 |
|
| 2015 |
Mensing S, Polepally AR, König D, Khatri A, Liu W, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. The Aaps Journal. PMID 26597291 DOI: 10.1208/S12248-015-9846-1 |
0.472 |
|
| 2015 |
Badri PS, Dutta S, Wang H, Podsadecki TJ, Polepally AR, Khatri A, Zha J, Chiu YL, Awni WM, Menon RM. Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir/Ritonavir (2D Regimen). Antimicrobial Agents and Chemotherapy. PMID 26459906 DOI: 10.1128/Aac.01778-15 |
0.421 |
|
| 2015 |
Khatri A, Menon R, Marbury TC, Lawitz E, Podsadecki TJ, Mullally V, Ding B, Awni WM, Bernstein B, Dutta S. Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment. Journal of Hepatology. PMID 26070406 DOI: 10.1016/J.Jhep.2015.05.029 |
0.42 |
|
| 2015 |
Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. Jama. 313: 1223-31. PMID 25706092 DOI: 10.1001/Jama.2015.1328 |
0.414 |
|
| 2015 |
Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, Wang H, Hu B, Coakley EP, Podsadecki TJ, Awni WM, Dutta S. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. Journal of Hepatology. 63: 20-9. PMID 25646891 DOI: 10.1016/J.Jhep.2015.01.026 |
0.427 |
|
| 2015 |
Khatri A, Mensing S, Podsadecki T, Awni W, Menon R, Dutta S. P0902 : Exposure-response analyses for efficacy (SVR12) for the direct acting antiviral regimen of ABT-450/R, ombitasvir with dasabuvir +/− ribavirin in subjects with HCV genotype 1 infection Journal of Hepatology. 62: S682. DOI: 10.1016/S0168-8278(15)31105-3 |
0.404 |
|
| 2015 |
Eckert D, Wang T, Mensing S, Khatri A, Dutta S, Menon R. P0823 : Pharmacokinetics of paritaprevir, ombitasvir, ritonavir and ribavirin in subjects with HCV genotype 4 infection Journal of Hepatology. 62: S645. DOI: 10.1016/S0168-8278(15)31026-6 |
0.385 |
|
| 2015 |
Mensing S, Sharma S, Eckert D, Polepally A, Khatri A, Podsadecki T, Awni W, Menon R, Dutta S. P0820 : Pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in subjects with HCV genotype 1 infection in phase 3 studies Journal of Hepatology. 62: S644. DOI: 10.1016/S0168-8278(15)31023-0 |
0.384 |
|
| 2015 |
Pockros P, Reddy K, Mantry P, Cohen E, Bennett M, Sulkowski M, Bernstein D, Podsadecki T, Cohen D, Shulman N, Wang D, Khatri A, Abunimeh M, Lawitz E. LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study Journal of Hepatology. 62: S257. DOI: 10.1016/S0168-8278(15)30147-1 |
0.347 |
|
| 2014 |
Eron JJ, Lalezari J, Slim J, Gathe J, Ruane PJ, Wang C, Elion R, Blick G, Khatri A, Hu YB, Gibbons K, Fredrick L, Co M, D'Amico R, Da Silva-Tillmann B, et al. Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens. Journal of the International Aids Society. 17: 19500. PMID 25394009 DOI: 10.7448/Ias.17.4.19500 |
0.413 |
|
| 2014 |
Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski MS, Xie W, Pilot-Matias T, Liossis G, Larsen L, Khatri A, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. The New England Journal of Medicine. 370: 222-32. PMID 24428468 DOI: 10.1056/Nejmoa1306227 |
0.443 |
|
| 2014 |
Khatri A, Williams BW, Fisher J, Brundage RC, Gurvich VJ, Lis LG, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK, Kirstein MN. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours. British Journal of Cancer. 110: 304-12. PMID 24300978 DOI: 10.1038/Bjc.2013.738 |
0.584 |
|
| 2013 |
Kowdley K, Lawitz E, Poordad F, Cohen D, Nelson D, Zeuzem S, Everson G, Kwo P, Foster G, Sulkowlski M, Xie W, Larsen L, Khatri A, Podsadecki T, Bernstein B. Safety and Efficacy of Interferon-free Regimens of ABT-450/r, ABT-267, ABT-333 ± Ribavirin in Patients with Chronic HCV GTI Infection: Results from the Aviator Study: 364 The American Journal of Gastroenterology. 108. DOI: 10.14309/00000434-201310001-00364 |
0.399 |
|
| 2013 |
Kowdley K, Lawitz E, Poordad F, Cohen D, Nelson D, Zeuzem S, Everson G, Kwo P, Foster G, Sulkowski M, Xie W, Larsen L, Khatri A, Podsadecki T, Bernstein B. 3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY Journal of Hepatology. 58: S2. DOI: 10.1016/S0168-8278(13)60005-7 |
0.408 |
|
| 2013 |
Rodriguez-Torres M, Nunes F, Cohen D, Xie W, Marincic C, Khatri A, Pilot-Matias T, Podsadecki T, Bernstein B. 514 Interferon-Free Regimens of Abt-450/R, Abt-267, Abt-333, and Ribavirin Achieve High Sustained Virologic Response 4 Weeks Post-Treatment (SVR4) Rates in Patients With Chronic HCV Genotype 1 Regardless of Race, Ethnicity, or Other Baseline Characteristics Gastroenterology. 144: S-949. DOI: 10.1016/S0016-5085(13)63530-1 |
0.392 |
|
| 2012 |
Khatri A, Brundage RC, Hull JM, Williams BW, Yee D, Kirstein MN. Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine. The Aaps Journal. 14: 1-9. PMID 22101930 DOI: 10.1208/S12248-011-9308-3 |
0.53 |
|
| 2012 |
Sullivan G, Rodriques-Torres M, Lawitz E, Poordad F, Kapoor M, Campbell A, Setze C, Xie W, Khatri A, Dumas E, Krishnan P, Pilot-Matias T, Williams L, Bernstein B. 1210 ABT-267 COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12 WEEK ANTIVIRAL AND SAFETY ANALYSIS Journal of Hepatology. 56: S480. DOI: 10.1016/S0168-8278(12)61222-7 |
0.399 |
|
| 2011 |
Khatri A, Gaber MW, Brundage RC, Naimark MD, Hanna SK, Stewart CF, Kirstein MN. Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid. Cancer Chemotherapy and Pharmacology. 68: 721-31. PMID 21161529 DOI: 10.1007/S00280-010-1542-3 |
0.529 |
|
| 2011 |
Bommakanti SV, Dudek AZ, Khatri A, Kirstein MN, Gada PD. Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors. American Journal of Clinical Oncology. 34: 597-602. PMID 21127410 DOI: 10.1097/Coc.0B013E3181F9441F |
0.338 |
|
| Show low-probability matches. |